Abstract
Background & Aim: Interferon-free DAA combinations allow an effective treatment of HCV recurrence after orthotopic liver transplantation (OLT), but the role of ribavirin (RBV) in the post transplant setting is still under debate. So far published data gained from IFN/RBV-free DAA-based regimens are sparse. We thus aimed to analyze safety and efficacy of IFN/RBV-free DAA-based regimens in HCV-recurrence after OLT.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
